2400万患者的福音!精神分裂症新药在美获批,市场潜力如何?

时代周报
27 Sep 2024

图片来源:图虫创意全球首款新型抗精神分裂症药物在美国获批。9月26日,百时美施贵宝(BMS)的FIC(First-in-class,全球首创)Cobenfy (xanomeline和trospium chloride复方,KarXT)获得美国食品药品监督管理局(FDA)批准上市,用于治疗成人精神分裂症,这是精神分裂症领域数十年来首个新型药物,也是首款获批治疗精神分裂症的毒蕈碱乙酰胆碱受体激动剂。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10